|apixaban and doac||1.38||0.4||1299||95|
|apixaban and vte doac||1.16||0.7||3032||37|
|apixaban a doac||1.69||0.6||9473||87|
|doac apixaban rivaroxaban||1.24||0.3||562||94|
|doac anticoagulant apixaban||0.99||1||7020||67|
|doac reversal apixaban||0.33||0.5||2230||22|
|is apixaban doac||0.69||0.9||2946||64|
|is apixaban a doac||1.28||0.1||9531||19|
Apixaban Apixaban (Eliquis) is a potent and direct inhibitor of FXa that specifically and reversibly inhibits both prothrombinase and clot-bound FXa . Food has no significant effect on the oral bioavailability of apixaban, which is approximately 60% at a dose of 2.5 mg and approximatively 50% at oral doses up to 10 mg [29,30].What is the plasma concentration of apixaban?
Consequently, the plasma concentration of DOACs can vary from patient to patient. The inter-patient variability is reported to be approximately 30% for dabigatran and apixaban and 30â€“40% for rivaroxaban .What are direct oral anticoagulants (DOACs)?
Direct oral anticoagulants are easy-to-use oral drugs that offer simple dosing with a fixed dose and short half-lives, but this strategy of DOAC management may be not optimal for some patient populations. Consequently, the plasma concentration of DOACs can vary from patient to patient.What are DOACs (direct factor Xa inhibitors)?
Available DOACs include the direct factor Xa inhibitors apixaban ( Eliquis ), edoxaban ( Lixiana â–¼), and rivaroxaban ( Xarelto â–¼) and the direct thrombin inhibitor dabigatran etexilate ( Pradaxa ). Use of DOACs increases the risk of bleeding and can cause serious, potentially fatal, bleeds.